These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 24262285)
1. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group. Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285 [TBL] [Abstract][Full Text] [Related]
2. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure. Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186 [TBL] [Abstract][Full Text] [Related]
4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
5. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia. Moore FR; Yang F; Press RD Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688 [TBL] [Abstract][Full Text] [Related]
6. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191 [TBL] [Abstract][Full Text] [Related]
7. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India. Bagadi S; Saikia T; Pany A; Das B Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027 [TBL] [Abstract][Full Text] [Related]
8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Wongboonma W; Thongnoppakhun W; Auewarakul CU Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255 [TBL] [Abstract][Full Text] [Related]
9. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). Marcé S; Cortés M; Zamora L; Cabezón M; Grau J; Millá F; Feliu E Exp Mol Pathol; 2015 Aug; 99(1):16-8. PubMed ID: 25913326 [TBL] [Abstract][Full Text] [Related]
10. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib. Lau A; Seiter K Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839 [TBL] [Abstract][Full Text] [Related]
11. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia. Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786 [TBL] [Abstract][Full Text] [Related]
12. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414 [TBL] [Abstract][Full Text] [Related]
13. Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Carella AM; Garuti A; Cirmena G; Catania G; Rocco I; Palermo C; Pica G; Pierri I; Miglino M; Ballestrero A; Gobbi M; Patrone F Leuk Lymphoma; 2010 Feb; 51(2):275-8. PubMed ID: 20038234 [TBL] [Abstract][Full Text] [Related]
14. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Kim DD; Lee H; Kamel-Reid S; Lipton JH Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256 [TBL] [Abstract][Full Text] [Related]
15. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Tiribelli M; Latagliata R; Luciano L; Castagnetti F; Gozzini A; Cambrin GR; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Montefusco E; Fava C; Fanin R; Pane F; Rosti G; Breccia M; Alimena G; Vigneri P Ann Hematol; 2013 Jan; 92(2):179-83. PubMed ID: 23053188 [TBL] [Abstract][Full Text] [Related]
16. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136 [TBL] [Abstract][Full Text] [Related]
17. Hematological and molecular response evaluation of CML patients on imatinib. Gupta A; Prasad K J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739 [TBL] [Abstract][Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
19. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]